The Reevaluation of Thrombin Time Using a Clot Waveform Analysis

Object: Although thrombin burst has attracted attention as a physiological coagulation mechanism, clinical evidence from a routine assay for it is scarce. This mechanism was therefore evaluated by a clot waveform analysis (CWA) to assess the thrombin time (TT). Material and Methods: The TT with a lo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hideo Wada, Yuhuko Ichikawa, Minoru Ezaki, Takeshi Matsumoto, Yoshiki Yamashita, Katsuya Shiraki, Motomu Shimaoka, Hideto Shimpo
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	CWA thrombin time platelet thrombin burst Medicine R
Acceso en línea:	https://doaj.org/article/9f8ca0f2ed7549e4965ce87bd70e3223
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9f8ca0f2ed7549e4965ce87bd70e3223
record_format	dspace
spelling	oai:doaj.org-article:9f8ca0f2ed7549e4965ce87bd70e32232021-11-11T17:30:31ZThe Reevaluation of Thrombin Time Using a Clot Waveform Analysis10.3390/jcm102148402077-0383https://doaj.org/article/9f8ca0f2ed7549e4965ce87bd70e32232021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/4840https://doaj.org/toc/2077-0383Object: Although thrombin burst has attracted attention as a physiological coagulation mechanism, clinical evidence from a routine assay for it is scarce. This mechanism was therefore evaluated by a clot waveform analysis (CWA) to assess the thrombin time (TT). Material and Methods: The TT with a low concentration of thrombin was evaluated using a CWA. We evaluated the CWA-TT of plasma deficient in various clotting factors, calibration plasma, platelet-poor plasma (PPP), and platelet-rich plasma (PRP) obtained from healthy volunteers, patients with thrombocytopenia, and patients with malignant disease. Results: Although the TT-CWA of calibration plasma was able to be evaluated with 0.01 IU/mL of thrombin, that of FVIII-deficient plasma could not be evaluated. The peak time of CWA-TT was significantly longer, and the peak height significantly lower, in various deficient plasma, especially in FVIII-deficient plasma compared to calibration plasma. The second peak of the first derivative (1st DP-2) was detected in PPP from healthy volunteers, and was shorter and higher in PRP than in PPP. The 1st DP-2 was not detected in PPP from patients with thrombocytopenia, and the 1st DP-2 in PRP was significantly lower in patients with thrombocytopenia and significantly higher in patients with malignant disease than in healthy volunteers. Conclusion: The CWA-TT became abnormal in plasma deficient in various clotting factors, and was significantly affected by platelets, suggesting that the CWA-TT may be a useful test for hemostatic abnormalities.Hideo WadaYuhuko IchikawaMinoru EzakiTakeshi MatsumotoYoshiki YamashitaKatsuya ShirakiMotomu ShimaokaHideto ShimpoMDPI AGarticleCWAthrombin timeplateletthrombin burstMedicineRENJournal of Clinical Medicine, Vol 10, Iss 4840, p 4840 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	CWA thrombin time platelet thrombin burst Medicine R
spellingShingle	CWA thrombin time platelet thrombin burst Medicine R Hideo Wada Yuhuko Ichikawa Minoru Ezaki Takeshi Matsumoto Yoshiki Yamashita Katsuya Shiraki Motomu Shimaoka Hideto Shimpo The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
description	Object: Although thrombin burst has attracted attention as a physiological coagulation mechanism, clinical evidence from a routine assay for it is scarce. This mechanism was therefore evaluated by a clot waveform analysis (CWA) to assess the thrombin time (TT). Material and Methods: The TT with a low concentration of thrombin was evaluated using a CWA. We evaluated the CWA-TT of plasma deficient in various clotting factors, calibration plasma, platelet-poor plasma (PPP), and platelet-rich plasma (PRP) obtained from healthy volunteers, patients with thrombocytopenia, and patients with malignant disease. Results: Although the TT-CWA of calibration plasma was able to be evaluated with 0.01 IU/mL of thrombin, that of FVIII-deficient plasma could not be evaluated. The peak time of CWA-TT was significantly longer, and the peak height significantly lower, in various deficient plasma, especially in FVIII-deficient plasma compared to calibration plasma. The second peak of the first derivative (1st DP-2) was detected in PPP from healthy volunteers, and was shorter and higher in PRP than in PPP. The 1st DP-2 was not detected in PPP from patients with thrombocytopenia, and the 1st DP-2 in PRP was significantly lower in patients with thrombocytopenia and significantly higher in patients with malignant disease than in healthy volunteers. Conclusion: The CWA-TT became abnormal in plasma deficient in various clotting factors, and was significantly affected by platelets, suggesting that the CWA-TT may be a useful test for hemostatic abnormalities.
format	article
author	Hideo Wada Yuhuko Ichikawa Minoru Ezaki Takeshi Matsumoto Yoshiki Yamashita Katsuya Shiraki Motomu Shimaoka Hideto Shimpo
author_facet	Hideo Wada Yuhuko Ichikawa Minoru Ezaki Takeshi Matsumoto Yoshiki Yamashita Katsuya Shiraki Motomu Shimaoka Hideto Shimpo
author_sort	Hideo Wada
title	The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
title_short	The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
title_full	The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
title_fullStr	The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
title_full_unstemmed	The Reevaluation of Thrombin Time Using a Clot Waveform Analysis
title_sort	reevaluation of thrombin time using a clot waveform analysis
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/9f8ca0f2ed7549e4965ce87bd70e3223
work_keys_str_mv	AT hideowada thereevaluationofthrombintimeusingaclotwaveformanalysis AT yuhukoichikawa thereevaluationofthrombintimeusingaclotwaveformanalysis AT minoruezaki thereevaluationofthrombintimeusingaclotwaveformanalysis AT takeshimatsumoto thereevaluationofthrombintimeusingaclotwaveformanalysis AT yoshikiyamashita thereevaluationofthrombintimeusingaclotwaveformanalysis AT katsuyashiraki thereevaluationofthrombintimeusingaclotwaveformanalysis AT motomushimaoka thereevaluationofthrombintimeusingaclotwaveformanalysis AT hidetoshimpo thereevaluationofthrombintimeusingaclotwaveformanalysis AT hideowada reevaluationofthrombintimeusingaclotwaveformanalysis AT yuhukoichikawa reevaluationofthrombintimeusingaclotwaveformanalysis AT minoruezaki reevaluationofthrombintimeusingaclotwaveformanalysis AT takeshimatsumoto reevaluationofthrombintimeusingaclotwaveformanalysis AT yoshikiyamashita reevaluationofthrombintimeusingaclotwaveformanalysis AT katsuyashiraki reevaluationofthrombintimeusingaclotwaveformanalysis AT motomushimaoka reevaluationofthrombintimeusingaclotwaveformanalysis AT hidetoshimpo reevaluationofthrombintimeusingaclotwaveformanalysis
_version_	1718432080171368448

The Reevaluation of Thrombin Time Using a Clot Waveform Analysis

Ejemplares similares